These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 38839505)

  • 1. Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract Carcinoma.
    Sternberg CN; Loriot Y; Choy E; Castellano D; Lopez-Rios F; Banna GL; Zengerling F; De Giorgi U; Gedye C; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Retz M; Gamulin M; Geczi L; Huddart RA; Calabrò F; Kandula G; Skamnioti P; Merseburger AS
    Eur Urol Focus; 2024 Jun; ():. PubMed ID: 38839505
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract.
    Sternberg CN; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Banna GL; De Giorgi U; Masini C; Bamias A; Garcia Del Muro X; Duran I; Powles T; Gamulin M; Zengerling F; Geczi L; Gedye C; de Ducla S; Fear S; Merseburger AS
    Eur Urol; 2019 Jul; 76(1):73-81. PubMed ID: 30910346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice.
    Cathomas R; Schardt J; Pless M; Llado A; Mach N; Riklin C; Haefeli J; Fear S; Stenner F
    Swiss Med Wkly; 2020 May; 150():w20223. PubMed ID: 32399958
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma.
    Bedke J; Merseburger AS; Loriot Y; Castellano D; Choy E; Duran I; Rosenberg JE; Petrylak DP; Dreicer R; Perez-Gracia JL; Hoffman-Censits JH; Van Der Heijden MS; Pavlova J; Thiebach L; de Ducla S; Fear S; Powles T; Sternberg CN
    Eur Urol Focus; 2021 Sep; 7(5):1084-1091. PubMed ID: 33168461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens.
    Perez-Gracia JL; Loriot Y; Rosenberg JE; Powles T; Necchi A; Hussain SA; Morales-Barrera R; Retz MM; Niegisch G; Durán I; Théodore C; Grande E; Shen X; Wang J; Nelson B; Derleth CL; van der Heijden MS
    Eur Urol; 2018 Mar; 73(3):462-468. PubMed ID: 29273410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma.
    Loriot Y; Sternberg CN; Castellano D; Oosting SF; Dumez H; Huddart R; Vianna K; Alonso Gordoa T; Skoneczna I; Fay AP; Nolè F; Massari F; Brasiuniene B; Maroto P; Fear S; Di Nucci F; de Ducla S; Choy E
    Eur J Cancer; 2020 Oct; 138():202-211. PubMed ID: 32905959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice.
    Merseburger AS; Castellano D; Powles T; Loriot Y; Retz M; Voortman J; Huddart RA; Gedye C; Van Der Heijden MS; Gurney H; Ong M; de Ducla S; Pavlova J; Fear S; Sternberg CN
    J Urol; 2021 Aug; 206(2):240-251. PubMed ID: 33835866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States.
    Pal SK; Hoffman-Censits J; Zheng H; Kaiser C; Tayama D; Bellmunt J
    Eur Urol; 2018 May; 73(5):800-806. PubMed ID: 29478735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
    Tural D; Ölmez ÖF; Sümbül AT; Artaç M; Özhan N; Akar E; Çakar B; Köstek O; Ekenel M; Erman M; Coşkun HŞ; Selçukbiricik F; Keskin Ö; Türköz FP; Oruç K; Bayram S; Yılmaz U; Bilgetekin İ; Yıldız B; Şendur MAN; Paksoy N; Dirican A; Erdem D; Selam M; Tanrıverdi Ö; Paydaş S; Urakçı Z; Atağ E; Güncan S; Ürün Y; Alkan A; Kaya AO; Özyükseler DT; Taşkaynatan H; Yıldırım M; Sönmez M; Başoğlu T; Gündüz Ş; Kılıçkap S
    Eur Urol Focus; 2021 Sep; 7(5):1061-1066. PubMed ID: 33008789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapy.
    Bamias A; Merseburger AS; Loriot Y; James N; Choy E; Castellano D; Lopez-Rios F; Calabrò F; Kramer M; de Velasco G; Zakopoulou R; Tzannis K; Sternberg CN
    ESMO Open; 2021 Jun; 6(3):100152. PubMed ID: 33984672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study.
    Petrylak DP; Powles T; Bellmunt J; Braiteh F; Loriot Y; Morales-Barrera R; Burris HA; Kim JW; Ding B; Kaiser C; Fassò M; O'Hear C; Vogelzang NJ
    JAMA Oncol; 2018 Apr; 4(4):537-544. PubMed ID: 29423515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.
    Bamias A; Davis ID; Galsky MD; Arranz JÁ; Kikuchi E; Grande E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; Panni S; Gumus M; Özgüroğlu M; Mariathasan S; Poloz Y; Bene-Tchaleu F; Lee C; Bernhard S; De Santis M
    Lancet Oncol; 2024 Jan; 25(1):46-61. PubMed ID: 38101431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.
    Rosenberg JE; Hoffman-Censits J; Powles T; van der Heijden MS; Balar AV; Necchi A; Dawson N; O'Donnell PH; Balmanoukian A; Loriot Y; Srinivas S; Retz MM; Grivas P; Joseph RW; Galsky MD; Fleming MT; Petrylak DP; Perez-Gracia JL; Burris HA; Castellano D; Canil C; Bellmunt J; Bajorin D; Nickles D; Bourgon R; Frampton GM; Cui N; Mariathasan S; Abidoye O; Fine GD; Dreicer R
    Lancet; 2016 May; 387(10031):1909-20. PubMed ID: 26952546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.
    van der Heijden MS; Loriot Y; Durán I; Ravaud A; Retz M; Vogelzang NJ; Nelson B; Wang J; Shen X; Powles T
    Eur Urol; 2021 Jul; 80(1):7-11. PubMed ID: 33902955
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.
    Grande E; Arranz JÁ; De Santis M; Bamias A; Kikuchi E; Del Muro XG; Park SH; De Giorgi U; Alekseev B; Mencinger M; Izumi K; Schutz FA; Puente J; Li JR; O'Donnell PH; Kalebasty AR; Ye D; Mariathasan S; Bene-Tchaleu F; Bernhard S; Lee C; Davis ID; Galsky MD
    Lancet Oncol; 2024 Jan; 25(1):29-45. PubMed ID: 38101433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
    Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
    Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
    Balar AV; Galsky MD; Rosenberg JE; Powles T; Petrylak DP; Bellmunt J; Loriot Y; Necchi A; Hoffman-Censits J; Perez-Gracia JL; Dawson NA; van der Heijden MS; Dreicer R; Srinivas S; Retz MM; Joseph RW; Drakaki A; Vaishampayan UN; Sridhar SS; Quinn DI; Durán I; Shaffer DR; Eigl BJ; Grivas PD; Yu EY; Li S; Kadel EE; Boyd Z; Bourgon R; Hegde PS; Mariathasan S; Thåström A; Abidoye OO; Fine GD; Bajorin DF;
    Lancet; 2017 Jan; 389(10064):67-76. PubMed ID: 27939400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
    Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma.
    Powles T; Assaf ZJ; Degaonkar V; Grivas P; Hussain M; Oudard S; Gschwend JE; Albers P; Castellano D; Nishiyama H; Daneshmand S; Sharma S; Sethi H; Aleshin A; Shi Y; Davarpanah N; Carter C; Bellmunt J; Mariathasan S
    Eur Urol; 2024 Feb; 85(2):114-122. PubMed ID: 37500339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
    Powles T; Durán I; van der Heijden MS; Loriot Y; Vogelzang NJ; De Giorgi U; Oudard S; Retz MM; Castellano D; Bamias A; Fléchon A; Gravis G; Hussain S; Takano T; Leng N; Kadel EE; Banchereau R; Hegde PS; Mariathasan S; Cui N; Shen X; Derleth CL; Green MC; Ravaud A
    Lancet; 2018 Feb; 391(10122):748-757. PubMed ID: 29268948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.